Definium Study Shows Rising GAD Prevalence, Highlights Treatment Gap

Event summary

  • Definium Therapeutics published a study showing GAD prevalence rose from 5.4% in 2020 to 6.6% in 2023, with 10.3% three-year cumulative prevalence.
  • GAD disproportionately affects women (67%) and is highly comorbid with major depressive disorder (MDD).
  • The study analyzed HIPAA-compliant data from the Komodo Healthcare Map™ claims database (2020-2023).
  • Last GAD treatment approval was in 2007, with many patients experiencing inadequate symptom relief.

The big picture

The study underscores the growing burden of GAD in the U.S., with over 1 in 10 adults affected. This aligns with broader trends of increasing mental health awareness and the need for more effective, accessible treatments. Definium's focus on psychedelic-based therapies positions it at the forefront of potential innovation in this space.

What we're watching

Treatment Innovation
Whether Definium can accelerate development of new GAD treatments given the 19-year approval gap.
Diagnostic Accuracy
The pace at which real-world claims data improves GAD diagnosis and treatment planning.
Comorbidity Management
How integrated approaches for GAD and MDD will evolve in clinical practice.